Research News and Research

RSS

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

A study published in the January 13, 2010 issue of the Journal of Neuroscience links a loss of smell function in Alzheimer's disease (AD) model animals with amyloid β (protein) accumulation in the brain, a distinguishing hallmark of Alzheimer's disease. Research conducted by NYU Langone Medical Center suggests that olfactory dysfunction, a common symptom of AD, may serve as an early diagnostic tool for the disease.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

Study recommends improvements for scaling up child survival programs

New child survival programs must engage evaluation teams from the start to identify the major causes of child mortality in intervention areas and to ensure that appropriate resources are available to scale up coverage and treatment, according to a retrospective evaluation led by researchers at the Johns Hopkins Bloomberg School of Public Health.

13 Jan 2010

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.

13 Jan 2010

Study finds financial ties between clinical study leaders and pharmaceutical companies

Reuters reports that a new study has found "cancer researchers who design clinical trials, analyze or interpret the data, or play other key scientific roles are four times more likely to have financial ties to industry than their counterparts who have lesser roles in these studies, such as recruiting study subjects or collecting the data."

13 Jan 2010

FBR releases new PSA, Jen's Story 2

The Foundation for Biomedical Research (FBR) announced today the release of its new PSA, "Jen's Story 2," as part of its ResearchSaves national campaign. The 60-second spot reunites viewers with Jen, a real biomedical researcher who specializes in breast cancer research and is battling the disease herself.

13 Jan 2010

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

According to the Office of National Drug Control Policy, prescription drug abuse is more prevalent than abuse of cocaine, heroin and methamphetamine. In fact, in the past year, prescription drug abuse ranked second only to marijuana use. In the face of this growing problem, Pisgah Labs, Inc. has just filed its eighth patent application on a technology that promises to curb prescription drug abuse.

13 Jan 2010

Retreating with gefitinib may benefit non-small cell lung cancer patients

Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.

13 Jan 2010

University of Leicester study provides new insights into preventer and reliever treatments for asthma

A new study at the University of Leicester is probing why asthma relief inhalers might actually make asthma worse- and what can be done about it.

13 Jan 2010

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

At least three tumor microRNAs appear to predict when first-line chemotherapy will prove ineffective in some patients with small cell lung cancer, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held Jan. 11-14, 2010.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

Majority of doctors appear to ignore FDA warning to screen high-risk medications

A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.

13 Jan 2010

Green tea could modulate smoke-induced lung cancer

Drinking green tea could modulate the effect of smoking on lung cancer. Results of this hospital-based, randomized study conducted in Taiwan were presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held here from Jan. 11-14, 2010.

13 Jan 2010

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Officials from the National Institutes of Health and the city of Washington, D.C. today announced the new D.C. Partnership for HIV/AIDS Progress, a collaborative research initiative between NIH and the D.C. Department of Health designed to decrease the rate of new HIV infections in the city, improve the health of district residents living with HIV infection, and strengthen the city's response to the HIV/AIDS epidemic.

13 Jan 2010

Study reveals new insights about stress in work-life balance

As many as 50 per cent of people bring their work home with them regularly, according to new research out of the University of Toronto that describes the stress associated with work-life balance and the factors that predict it.

13 Jan 2010

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

It is no longer a theory. Percutaneous coronary intervention (PCI) or coronary angioplasty is the best treatment for a person presenting with STEMI (ST- elevation myocardial infarction), a heart attack caused by complete obstruction of a coronary artery.

13 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

Masimo announces strategic investment totaling $3.5M in SEDLine

Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, today announced a strategic investment totaling $3.5 million in SEDLine, Inc., a newly-formed private company that was formerly operated by Hospira, Inc.

13 Jan 2010

Research News and Research

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Study recommends improvements for scaling up child survival programs

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Study finds financial ties between clinical study leaders and pharmaceutical companies

FBR releases new PSA, Jen's Story 2

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

Retreating with gefitinib may benefit non-small cell lung cancer patients

University of Leicester study provides new insights into preventer and reliever treatments for asthma

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

Majority of doctors appear to ignore FDA warning to screen high-risk medications

Green tea could modulate smoke-induced lung cancer

NIH, D.C. Department of Health partner to decrease the rate of new HIV infections

Study reveals new insights about stress in work-life balance

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Research reveals how cancers shield themselves from immune attack

Masimo announces strategic investment totaling $3.5M in SEDLine

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News